SDS® Therapy
Heart Failure (specifically with reduced ejection fraction and preserved ventricular synchrony)
Phase 2Active
Key Facts
Indication
Heart Failure (specifically with reduced ejection fraction and preserved ventricular synchrony)
Phase
Phase 2
Status
Active
Company
About VisCardia
VisCardia is a clinical-stage medical device company targeting the massive and growing heart failure market with its novel SDS® therapy. The technology involves implantable stimulation of the diaphragm to improve ventricular function, offering a potential alternative for patients inadequately managed by drugs but not candidates for complex surgeries. Having completed initial European clinical studies, the company is positioning its data for presentation at major cardiology conferences as it advances toward later-stage development and potential commercialization.
View full company profile